BeyondSpring enrolls first patient in study of Plinabulin, Keytruda, Docetaxel

BeyondSpring (BYSI) announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s (MRK) anti-PD-1 therapy Keytruda and Docetaxel for previously treated patients with metastatic non-small cell lung cancer, NSCLC, and progressive disease after immunotherapy alone or in combination with platinum-doublet chemotherapy. Most patients experience disease progression after immune checkpoint inhibitor-based treatment regimens. BeyondSpring’s triple-combination therapy has the potential to improve ICI resistance and provide a new treatment option for metastatic NSCLC patients previously treated with an immunotherapy. The study is actively recruiting at Peking Union Medical College Hospital in Beijing, China. "As 25 to 30 percent of patients suffering from metastatic NSCLC have a life expectancy of under three months4, it is our mission to find better treatments that extend these patients’ lives so that they can see a child being born or a graduation from high school – every moment matters. Enrolling the first patient in this trial is a pivotal moment as we look to bring more promising therapies to patients in need. This new combination approach has the potential to make meaningful differences in patient quality of life and survival," added Dr. Lan Huang, Co-Founder, Chairman and CEO at BeyondSpring.